| Interim Health Care Of Southern Iowa | |
| 209 N Clinton St, Albia, Iowa 52531 | |
| (641) 932-2513 | |
| Not Available |
| Name | Interim Health Care Of Southern Iowa |
|---|---|
| Location | 209 N Clinton St, Albia, Iowa |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Home Health Aide |
| Medicare ID | 167421 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 50150, 52501, 52531, 52536, 52544, 52553, 52571, 52581 |
| NPI Number | 1134490857 |
| Organization Name | SOUTHERN IOWA HOME HEALTH, LLC |
| Doing Business As | INTERIM HEALTHCARE OF SOUTHERN IOWA |
| Address | 209 N. Clinton St., Albia, IA 52531 |
| Phone Number | 641-932-2513 |
News Archive
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
A new study of mutations in cancer genomes shows how researchers can begin to distinguish the 'driver' mutations that push cells towards cancer from the 'passenger' mutations that are a by-product of cancer cell development. The study also shows that at least one in nine genes can be removed without killing human cells.
"The first field trial for a 'lab on a chip' accurately detected both HIV and syphilis among a Rwandan population, researchers reported Sunday" in an online report published by Nature Medicine, the Washington Post reports.
Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in Aris Teleradiology.
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
› Verified 5 days ago
| Quality Rating: | Not Available* |
| * The number of patient episodes for this measure is too small to report. | |
News Archive
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
A new study of mutations in cancer genomes shows how researchers can begin to distinguish the 'driver' mutations that push cells towards cancer from the 'passenger' mutations that are a by-product of cancer cell development. The study also shows that at least one in nine genes can be removed without killing human cells.
"The first field trial for a 'lab on a chip' accurately detected both HIV and syphilis among a Rwandan population, researchers reported Sunday" in an online report published by Nature Medicine, the Washington Post reports.
Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in Aris Teleradiology.
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
› Verified 5 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | Not Available |
| Health team communicated well with them | Not Available |
| Health team discussed medicines, pain, and home safety | Not Available |
| How patients rated overall care from agency | Not Available |
News Archive
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
A new study of mutations in cancer genomes shows how researchers can begin to distinguish the 'driver' mutations that push cells towards cancer from the 'passenger' mutations that are a by-product of cancer cell development. The study also shows that at least one in nine genes can be removed without killing human cells.
"The first field trial for a 'lab on a chip' accurately detected both HIV and syphilis among a Rwandan population, researchers reported Sunday" in an online report published by Nature Medicine, the Washington Post reports.
Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in Aris Teleradiology.
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
› Verified 5 days ago
The patient survey data of Interim Health Care Of Southern Iowa is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 82 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 77 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 87 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 77 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 74 | 78 |
News Archive
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
A new study of mutations in cancer genomes shows how researchers can begin to distinguish the 'driver' mutations that push cells towards cancer from the 'passenger' mutations that are a by-product of cancer cell development. The study also shows that at least one in nine genes can be removed without killing human cells.
"The first field trial for a 'lab on a chip' accurately detected both HIV and syphilis among a Rwandan population, researchers reported Sunday" in an online report published by Nature Medicine, the Washington Post reports.
Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in Aris Teleradiology.
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
› Verified 5 days ago
Interim Health Care Of Southern Iowa Location: 209 N Clinton St, Albia, Iowa 52531 Ratings: NA Phone: (641) 932-2513 |